Hepatitis B virus X protein in the proliferation of hepatocellular carcinoma cells

Frontiers in Bioscience

Volumn 18, Issue 4, 2013, Pages 1256-1265

  Gong, Peng ^a   Zhang, Xianbin ^a   Zhang, Jian ^a   Zhang, Jing ^a   Luo, Haifeng ^a   Wang, Zhongyu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus X protein; Hepatocellular carcinoma; Proliferation; Review

Indexed keywords

EID: 84880534027     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4177     Document Type: Article

References (102)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917 (2010).
2. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5- S16 (2004). (Pubitemid 39423365)
3. Sun TT, Chu YY: Carcinogenesis and prevention strategy of liver cancer in areas of prevalence. J Cell Physiol Suppl3, 39- 44 (1984).
4. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27, 1485-91 (2009).
5. World Health Organization. Mortality database: 2012 [updated 2012 November]; Available from: www.who.int/whosis/en.
6. Chen CJ, Yu MW, Liaw YF: Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12, S294-S308 (1997).
7. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-76 (2007). (Pubitemid 46890874)
8. Marotta F, Vangieri B, Cecere A, Gattoni A: The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter 155, 187-199 (2004). (Pubitemid 44911923)
9. Cougot D, Neuveut C, Buendia MA: HBV induced carcinogenesis. J Clin Virol 34, Suppl 1, S75-S78 (2005).
10. Anzola M: Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11, 383-393 (2004). (Pubitemid 39336219)
11. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW: Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 31, 1243-1248 (2007). (Pubitemid 47029929)
12. Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D: Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat 12, 635-641 (2005). (Pubitemid 41532495)
13. Dewantoro O, Gani RA, Akbar N: Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53. Acta Med Indones 38, 154-159 (2006).
14. Park US, Su JJ, Ban KC, Qin L, Lee EH: Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1. Gene 251, 73-80 (2000). (Pubitemid 30339417)
15. Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-Buey L, Moreno-Otero R: Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann Hepatol 6, 208-213 (2007).
16. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G: Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106, 334-341 (2003). (Pubitemid 36870393)
17. Tommasi S, Pinto R, Pilato B, Paradiso A: Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des 13, 3279-3287 (2007). (Pubitemid 350201682)
18. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46, 249-279 (2006). (Pubitemid 44301348)
19. Kasai Y, Takeda S, Takagi H: Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Semin Surg Oncol 12, 155-159 (1996). (Pubitemid 26154619)
20. Kew MC: Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 26, 144-152 (2011).
21. Liu XH, Lin J, Zhang SH, Zhang SM, Feitelson MA: COOHterminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma. World J Gastroenterol 14, 1346-1352 (2008). (Pubitemid 351425212)
22. Kim CM, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317-320 (1991). (Pubitemid 21896589)
23. Zhu H, Wang Y, Chen J, Cheng G, Xue J: Transgenic mice expressing hepatitis B virus X protein are more susceptible to carcinogen induced hepatocarcinogenesis. Exp Mol Pathol 76, 44-50 (2004). (Pubitemid 38096318)
24. Luedde T, Schwabe RF: NF-kappaB in the liver- linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8, 108-118 (2011).
25. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y: Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat 7, 268-275 (2000).
26. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SAl: Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140, 450-457; discussion 457-458 (2005).
27. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG: AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6th ed. New York: Springer 469 (2002).
28. Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW, Lee SD: The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 102, 1920-1930 (2007).
29. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 115, 209-218 (2005). (Pubitemid 40385459)
30. Martín-Vílchez S, Sanz-Cameno P, Rodríguez- Muñoz Yl: The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 47, 1872-83 (2008). (Pubitemid 351945555)
31. Guo GH, Tan DM, Zhu PA, Liu F: Hepatitis B virus X protein promotes proliferation and upregulates TGF-beta1 and CTGF in human hepatic stellate cell line, LX-2. Hepatobiliary Pancreat Dis Int 8, 59-64 (2009).
32. Madden CR, Finegold MJ, Slagle BL: Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol 75, 3851-8 (2001). (Pubitemid 32246394)
33. Pang R, Lee TK, Poon RT: Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology 132, 1088-103 (2007). (Pubitemid 46440863)
34. Lu KP, Hanes SD, Hunter T: A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380, 544-547 (1996). (Pubitemid 26111332)
35. Lu KP: Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 29, 200-209 (2004). (Pubitemid 38472025)
36. Zhou XZ, Lu PJ, Wulf G, Lu KP: Phosphorylationdependent prolyl isomerization: a novel signaling regulatory mechanism. Cell Mol Life Sci 56, 788-806 (1999).
37. Kim MR, Choi HS, Heo TH, Hwang SW, Kang KW: Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells. Biochem Biophys Res Commun 369, 547-553 (2008).
38. Terradillos O, Billet O, Renard CA: The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14, 395-404 (1997). (Pubitemid 27087102)
39. Shukla SK, Kumar V: Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation. FEBS J 279, 3859-71 (2012).
40. Feng SL, Guo Y, Factor VM: The Fn14 immediateearly response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156, 1253-61 (2000). (Pubitemid 30660004)
41. Yang L, He J, Chen L, Wang G: Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells. Med Oncol 26, 445-51 (2009).
42. Zhang JL, Zhao WG, Wu KL: Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin. Arch Virol 150, 721-41 (2005).
43. Zhang WY, Xu FQ, Shan CL, Xiang R, Ye LH, Zhang XD: Gene expression profiles of human liver cells mediated by hepatitis B virus X protein. Acta Pharmacol Sin 30, 424-34 (2009).
44. Wu CG, Salvay DM, Forgues M: Distinctive gene expression profiles associated with Hepatitis B virus x protein. Oncogene 20, 3674-82 (2001). (Pubitemid 32624959)
45. Gouas DA, Shi H, Hautefeuille AH: Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis 31, 1475-82 (2010).
46. Venters BJ, Pugh BF: How eukaryotic genes are transcribed. Crit Rev Biochem Mol Biol 44, 117-141 (2009).
47. Sims RJ, Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev 18, 2437-2468 (2004). (Pubitemid 39362887)
48. Sakurai H, Ishihama A: Transcription organization and mRNA levels of the genes for all 12 subunits of the fission yeast RNA polymerase II. Genes Cells 6, 25-36 (2001). (Pubitemid 32156751)
49. Cramer P, Bushnell DA, Fu J: Architecture of RNA polymerase II and implications for the transcription mechanism. Science 288, 640-649 (2000). (Pubitemid 30241562)
50. Yang H, Gu J, Zheng Q, Li M: RPB5-mediating protein is required for the proliferation of hepatocellular carcinoma cells. J Biol Chem 286, 11865-74 (2011).
51. Yang Y, Zheng L, Chen Y: Study of HBV X protein and RMP, an RPB5 mediate protein competitively interacting with general transcription factor TF2B. Zhonghua Gan Zang Bing Za Zhi 8, 15-17 (2000).
52. Deng WS, Roberts SGE: TFIIB and the regulation of transcription by RNA polymerase II. Chromosoma 116, 417-429 (2007). (Pubitemid 47456910)
53. Haviv I, Shamay M, Doitsh G: Hepatitis B virus pX targets TFIIB in transcription coactivation. Mol Cell Biol 18, 1562-1569 (1998). (Pubitemid 28100922)
54. Li L, Zhang A, Cao X, Chen J, Xia Y, Zhao H, Shen A: General Transcription Factor IIB Overexpression and a Potential Link to Proliferation in Human HepatocellularCarcinoma. Pathol Oncol Res (2012) [Epub ahead of print].
55. Okamoto T, Sanda T and Asamitsu K: NF-kappa B signaling and carcinogenesis. Curr Pharm Des 13, 447-462 (2007).
56. Rosette C and Karin M: Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274, 1194- 1197 (1996). (Pubitemid 26389285)
57. Um HR, Lim WC, Chae SY, Park S, Park JH and Cho H: Raf-1 and protein kinase B regulate cell survival through the activation of NF-kappaB in hepatitis B virus Xexpressing cells. Virus Res 125, 1-8 (2007). (Pubitemid 46413380)
58. Factor V, Oliver AL, Panta GR, Thorgeirsson SS, Sonenshein GE and Arsura M: Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. Hepatology 34, 32-41 (2001). (Pubitemid 32591480)
59. An J and Rettig MB: Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 25, 7546-7556 (2005). (Pubitemid 41170117)
60. Kim SY, Kim JC, Kim JK: Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1. BMB Rep 41, 158-63 (2008).
61. Lu B, Guo H, Zhao J: Increased expression of iASPP, regulated by hepatitis B virus X protein-mediated NF-κB activation, in hepatocellular carcinoma. Gastroenterology 139, 2183-2194.(2010).
62. Yun C, Um HR, Jin YH: NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett 184, 97-104 (2002). (Pubitemid 34718111)
63. Kim A, Kwon OS, Kim SO: Caspase-3 activation as a key factor for HBx-transformed cell death. Cell Prolif 41, 755-74 (2008).
64. Yen CJ, Lin YJ, Yen CS: Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One 7, e41931 (2012).
65. Wang Y, Lu Y, Toh ST: Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 53, 57-66 (2010).
66. Fu X, Tan D, Hou Z, Hu Z, Liu G: miR-338-3p Is Down- Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3'-UTR Region of CyclinD1. Int J Mol Sci 13, 8514-39 (2012).
67. Du Y, Kong G, You X: Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287, 26302-11 (2012).
68. Qiao L, Leach K, McKinstry R: Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology 34, 906-17 (2001). (Pubitemid 33032025)
69. Cheng P, Li Y, Yang L: Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncol Rep 22, 1101-7 (2009).
70. Gearhart TL, Bouchard MJ: The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol 84, 2675-86 (2010).
71. Wu BK, Li CC, Chen HJ: Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 340, 916-28 (2006).
72. Xu J, Yun X, Jiang J: Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology 52, 142- 54 (2010).
73. Wang F, Zhou H, Xia X, Sun Q, Wang Y, Cheng B: Activated Notch signaling is required for hepatitis B virus X protein to promote proliferation and survival of human hepatic cells. Cancer Lett 298, 64-73 (2010).
74. Gao J, Chen C, Hong L: Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun 356, 341-7 (2007). (Pubitemid 46452552)
75. Wu G, Yu F, Xiao Z: Hepatitis B virus X protein downregulates expression of the miR-16 family inmalignant hepatocytes in vitro. Br J Cancer 105, 146-53 (2011).
76. Wang Q, Zhang W, Liu Q: A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. Neoplasia 12, 103-15 (2010).
77. Shan C, Xu F, Zhang S, You J: Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p- ERK1/2. Cell Res 20, 563-75 (2010).
78. Kong GY, Zhang JP, Zhang S, Shan CL, Ye LH, Zhang XD: Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2. Acta Pharmacol Sin 32, 1173-80 (2011).
79. Yang B, Bouchard MJ: The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol 86, 313-27 (2012).
80. Chen L, Hu L, Li L: Dysregulation of β-catenin by hepatitis B virus X protein in HBV-infected human hepatocellular carcinomas. Front Med China 4, 399-411 (2010).
81. Xu J, Liu H, Chen L: Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by upregulating and activating p21-activated kinase 1. Gastroenterology 143, 199-212.(2012).
82. Tang R, Kong F, Hu L: Role of hepatitis B virus X protein in regulating LIM and SH3 protein 1 (LASP-1) expression to mediate proliferation and migration of hepatoma cells. Virol J 9, 163 (2012).
83. Bergametti F, Prigent S, Luber B: The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Oncogene 18, 2860-2871 (1999). (Pubitemid 29250876)
84. Paterlini P, Poussin K, Kew M, Franco D, Brechot C: Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 21, 313-321 (1995).
85. Zhu M, London WT, Duan LX, and Feitelson MA: The value of hepatitis B x antigen as a prognostic marker in the development of hepatocellular carcinoma. Int J Cancer 55, 571-576 (1993). (Pubitemid 23328940)
86. Wang WL, London WT, Feitelson MA: Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 51, 4971-4977 (1991).
87. Wei Y, Etiemble J, Fourel G, Vitvitski-Trepo L, Buendia MA: Hepadna virus integration generates viruscell cotranscripts carrying 3- truncated X genes in human and woodchuck liver tumors. J Med Virol 45, 82-90 (1995).
88. Chen WN, Oon CJ, Leong AL, Koh S, Teng SW: Expression of integrated hepatitis B virus X variants in human hepatocellular carcinomas and its significance. Biochem Biophys Res Commun 276, 885-892 (2000).
89. Hsia CC, Nakashima Y, and Tabor E: Deletion mutants of the hepatitis B virus X gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 241, 726-729 (1997). (Pubitemid 28036725)
90. Wollersheim M, Debelka U: Hofschneider PHA transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 3, 545- 552 (1988). (Pubitemid 19003660)
91. Poussin K, Dienes H, Sirma H: Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 80, 497-505 (1999). (Pubitemid 29047511)
92. Yamamoto S, Nakatake H, Kawamoto S, Takimoto M, Koshy R, Matsubara K: Transactivation of cellular promoters by an integrated hepatitis B virus DNA. Biochem Biophys Res Commun 192, 111-118 (1993). (Pubitemid 23205275)
93. Schluter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH: Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 9, 3335-3344 (1994).
94. Tsuei DJ, Hsu TY, Chen JY, Chang MH, Hsu HC, Yang CS: Analysis of integrated hepatitis B virus DNA and flanking cellular sequences in a childhood hepatocellular carcinoma. J Med Virol 42, 287-293 (1994).
95. Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF: Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 19, 5213-5220 (2000).
96. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S: Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients, comparative analysis of 40 full-length isolates. Arch Virol 143, 2313-2326 (1998). (Pubitemid 29020107)
97. Baptista M, Kramvis A, Kew MC: High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 29, 946-953 (1999). (Pubitemid 29109614)
98. Hsia CC., Yuwen H, Tabor E: Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 348, 625-626 (1996). (Pubitemid 26283926)
99. Tu H, Bonura C, Giannini C, Mouly H: Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 61, 7803-10 (2001). (Pubitemid 33049368)
100. Liu XH, Lin J, Cao XZ, Zheng JM, Chen Y, Zhu MH: Biological impact of the COOH-terminal 40 amino aciddeletions of hepatitis B virus X protein in hepatocellular carcinoma cells. Zhonghua Yi Xue Za Zhi 85, 825-30 (2005). (Pubitemid 40484872)
101. Liu XH, Zhu MH, Cao XZ, Zheng JM, Chen Y: Biological effects of COOH-terminal amino acid deletions of hepatitis B virus X protein on hepatocellular carcinoma cell line Huh7. Ai Zheng 24, 1213-9 (2005).
102. Liu X, Zhang S, Lin J: Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochem Biophys Res Commun 373, 643-7 (2008).